{"id":55207,"date":"2023-03-27T14:07:26","date_gmt":"2023-03-27T12:07:26","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"modified":"2023-03-27T14:07:26","modified_gmt":"2023-03-27T12:07:26","slug":"recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","title":{"rendered":"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days"},"content":{"rendered":"
\n

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics<\/a>,<\/span> a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April 3, 2023 at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days.\n<\/p>\n

<\/a><\/p>\n

\nAbout ReCode Therapeutics<\/b>\n<\/p>\n

\nReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of messenger RNA (mRNA) and gene correction therapeutics. ReCode\u2019s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform is the foundation for ReCode\u2019s pipeline of disease-modifying mRNA and gene correction therapeutics. ReCode\u2019s lead programs are focused on primary ciliary dyskinesia and cystic fibrosis. ReCode is leveraging its SORT LNP platform and nucleic acid technologies to expand its pipeline with therapeutics that use mRNA-mediated replacement and gene correction in target organs with precision targeting of disease-relevant cells. In 2022, ReCode was named among Fierce Biotech\u2019s \u201cFierce 15\u201d as one of the most promising early-stage biotechnology companies in the industry, and was described by Nature as one of the \u201cSeven Technologies to Watch in 2022\u201d for its SORT LNP platform. For more information, visit www.recodetx.com<\/a> and follow us on LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/span><\/b>
Sarah McCabe
\n
Stern IR
\n
sarah.mccabe@sternir.com<\/a>
IR@recodetx.com<\/a>\n<\/p>\n

\nMedia Contact:<\/span><\/b>
Tara Cooper
\n
The Grace Communication Group
\n
tara@gracegroup.us<\/a>
650-303-7306\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April 3, 2023 at the virtual … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55207","6":"format-standard","7":"category-industry"},"yoast_head":"\nReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April 3, 2023 at the virtual ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T12:07:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230327005051\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days\",\"datePublished\":\"2023-03-27T12:07:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"},\"wordCount\":277,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230327005051\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\",\"name\":\"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230327005051\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\",\"datePublished\":\"2023-03-27T12:07:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230327005051\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230327005051\\\/en\\\/1498350\\\/21\\\/ReCode_Logo_Primary_Web%402000px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","og_locale":"en_US","og_type":"article","og_title":"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Pharma Trend","og_description":"MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that David Lockhart, Ph.D., President and Chief Scientific Officer of ReCode Therapeutics, will participate in a fireside chat at 9:35 a.m. ET on Monday, April 3, 2023 at the virtual ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-27T12:07:26+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230327005051\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days","datePublished":"2023-03-27T12:07:26+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"},"wordCount":277,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230327005051\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","url":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/","name":"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230327005051\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","datePublished":"2023-03-27T12:07:26+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230327005051\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230327005051\/en\/1498350\/21\/ReCode_Logo_Primary_Web%402000px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/recode-therapeutics-to-present-at-guggenheim-healthcare-talks-genomic-medicines-and-rare-disease-days\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ReCode Therapeutics to Present at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55207"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55207\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}